GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

Bilateral versus unilateral cases of chronic rhinosinusitis with nasal polyps have notable clinical and laboratory ...

a new biologic treatment for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab would be the first biologic of its kind to offer a six ...

A few baseline characteristics can predict the need for recurrent endoscopic sinus surgery among patients with CRSwNP.

Concerning CRSwNP, GSK intends to secure approval in ... If approved, depemokimab will be the first ultra-long-acting biologic that requires the administration of only one dose every six months.

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

13 CRSwNP is a chronic condition that affects up to 4% of the ... With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on ...

About Asthma, CRSwNP and type 2 inflammation ... With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics, and inhaled medicines, we are focused on improving ...

LONDON - GSK plc (LSE/NYSE: LON:GSK) has announced the acceptance of regulatory filings in China and Japan for depemokimab, a new biologic treatment for asthma with type 2 inflammation and chronic ...